Table 1 Baseline characteristics of 260 patients with systolic heart failure
From: Prognostic value of alveolar volume in systolic heart failure: a prospective observational study
Characteristic | Number or Median | (Percent or IQR) |
|---|---|---|
Age, years | 68 | (58–75) |
Male gender | 207 | (80) |
BMI, kg/m2 | 26 | (24–29) |
Current smoker | 50 | (19) |
NYHA class III-IV | 84 | (32) |
LVEF, % | 32 | (25–40) |
Cardiothoracic ratio >0.5 | 162 | (62) |
NT-ProBNP, pg/mL | 1302 | (531–3028) |
Hemoglobin, g/dL | 13.7 | (12.4–14.9) |
Creatinine, mmol/L | 101 | (82–127) |
FEV1, % predicted | 87 | (72–101) |
DLCO, % predicted | 70 | (61–81) |
COPD | 65 | (25) |
Ventilatory restriction | 53 | (20) |
Coronary artery disease | 115 | (44) |
Hypertension | 141 | (54) |
Persistent atrial fibrillation | 51 | (20) |
Prior stroke | 21 | (8) |
Diabetes | 82 | (32) |
Dyslipidemia | 109 | (42) |
Beta-blockers | 223 | (86) |
ACE-inhibitors | 150 | (58) |
Angiotensin receptor antagonists | 75 | (29) |
Loop diuretics | 225 | (87) |
Potassium sparing drugs | 175 | (67) |
Warfarin | 42 | (16) |
Implanted pace-maker | 35 | (13) |
Implanted defibrillator | 13 | (5) |